published meta-analysis   sensitivity analysis   studies

anti-inflammatory therapies in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsShi, 2020 0.53 [0.01; 27.55] 0.53[0.01; 27.55]Shi, 202010%100NAnot evaluable deathsdetailed resultsShi, 2020 0.53 [0.01; 27.55] 0.53[0.01; 27.55]Shi, 202010%100NAnot evaluable serious adverse eventsdetailed resultsShi, 2020 1.08 [0.04; 32.96] 1.08[0.04; 32.96]Shi, 202010%100NAnot evaluable adverse eventsdetailed resultsShi, 2020 0.88 [0.38; 2.03] 0.88[0.38; 2.03]Shi, 202010%100NAnot evaluable0.22.01.0relative treatment effectwww.metaEvidence.org2024-04-28 10:54 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615 - roots T: 290